News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
287,807 Results
Type
Article (15249)
Company Profile (298)
Press Release (272253)
Multimedia
Podcasts (97)
Webinars (12)
Section
Business (79983)
Career Advice (167)
Deals (13399)
Drug Delivery (44)
Drug Development (50829)
Employer Resources (31)
FDA (5905)
Job Trends (5190)
News (145432)
Policy (10087)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (942)
Accelerated approval (28)
Adcomms (14)
Allergies (102)
Alliances (21772)
ALS (162)
Alzheimer's disease (1133)
Antibody-drug conjugate (ADC) (377)
Approvals (6188)
Artificial intelligence (353)
Autoimmune disease (244)
Automation (11)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (121)
Biotechnology (228)
Bladder cancer (121)
Brain cancer (57)
Breast cancer (415)
Cancer (3911)
Cardiovascular disease (290)
Career advice (156)
Career pathing (10)
CAR-T (268)
CDC (8)
Celiac Disease (1)
Cell therapy (714)
Cervical cancer (22)
Clinical research (44786)
Collaboration (1428)
Company closure (3)
Compensation (738)
Complete response letters (55)
COVID-19 (1126)
CRISPR (105)
C-suite (753)
Cystic fibrosis (120)
Data (5634)
Denatured (20)
Depression (113)
Dermatology (55)
Diabetes (305)
Diagnostics (1441)
Digital health (17)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (258)
Drug pricing (52)
Drug shortages (3)
Duchenne muscular dystrophy (272)
Earnings (32756)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (53290)
Executive appointments (689)
FDA (8059)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (17)
Frontotemporal dementia (31)
Funding (1175)
Gene editing (224)
Generative AI (30)
Gene therapy (601)
GLP-1 (557)
Government (1185)
Grass and pollen (3)
Guidances (173)
Healthcare (6696)
HIV (27)
Huntington's disease (50)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (86)
Immunology and inflammation (235)
Immuno-oncology (76)
Indications (127)
Infectious disease (1276)
Inflammatory bowel disease (182)
Inflation Reduction Act (10)
Influenza (55)
Intellectual property (200)
Interviews (19)
IPO (7364)
IRA (13)
Job creations (872)
Job search strategy (133)
JPM (41)
Kidney cancer (9)
Labor market (29)
Layoffs (252)
Leadership (13)
Legal (1404)
Liver cancer (46)
Longevity (24)
Lung cancer (515)
Lymphoma (290)
Machine learning (33)
Management (7)
Manufacturing (511)
MASH (161)
Medical device (2701)
Medtech (2720)
Mergers & acquisitions (6757)
Metabolic disorders (883)
mRNA (158)
Multiple sclerosis (122)
NASH (14)
Neurodegenerative disease (316)
Neuropsychiatric disorders (81)
Neuroscience (2277)
Neurotech (1)
NextGen: Class of 2026 (2039)
Non-profit (880)
Now hiring (39)
Obesity (393)
Opinion (141)
Ovarian cancer (181)
Pain (133)
Pancreatic cancer (219)
Parkinson's disease (295)
Partnered (12)
Patents (383)
Patient recruitment (492)
Peanut (47)
People (27167)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15874)
Phase 2 (20850)
Phase 3 (13123)
Pipeline (5765)
Policy (106)
Postmarket research (853)
Preclinical (6747)
Press Release (30)
Prostate cancer (193)
Psychedelics (58)
Radiopharmaceuticals (276)
Rare diseases (854)
Real estate (1460)
Recruiting (12)
Regulatory (10506)
Reports (21)
Research institute (983)
Resumes & cover letters (20)
Rett syndrome (35)
RNA editing (27)
RSV (24)
Schizophrenia (145)
Series A (230)
Series B (159)
Service/supplier (1)
Sickle cell disease (90)
Special edition (20)
Spinal muscular atrophy (125)
Sponsored (17)
Startups (2028)
State (1)
Stomach cancer (5)
Supply chain (38)
Tariffs (21)
The Weekly (75)
Vaccines (392)
Venture capital (86)
Weight loss (211)
Women's health (45)
Worklife (2)
Date
Today (129)
Last 7 days (356)
Last 30 days (2061)
Last 365 days (17912)
2026 (7812)
2025 (18101)
2024 (20541)
2023 (22414)
2022 (26825)
2021 (27807)
2020 (23359)
2019 (16231)
2018 (11745)
2017 (13746)
2016 (11847)
2015 (14356)
2014 (10400)
2013 (7492)
2012 (7542)
2011 (7618)
2010 (7432)
Location
Africa (155)
Alabama (72)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18631)
Australia (3193)
California (8451)
Canada (2162)
China (981)
Colorado (303)
Connecticut (313)
Delaware (288)
Europe (40071)
Florida (1086)
Georgia (249)
Hawaii (2)
Idaho (17)
Illinois (495)
India (45)
Indiana (196)
Iowa (8)
Japan (293)
Kansas (83)
Kentucky (11)
Louisiana (14)
Maine (12)
Maryland (873)
Massachusetts (6707)
Michigan (127)
Minnesota (302)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (47)
New Hampshire (22)
New Jersey (1921)
New Mexico (13)
New York (2099)
North Carolina (988)
North Dakota (7)
Northern California (4273)
Ohio (212)
Oklahoma (11)
Oregon (23)
Pennsylvania (1559)
Puerto Rico (11)
Rhode Island (27)
South America (217)
South Carolina (12)
Southern California (3384)
Tennessee (50)
Texas (1146)
United States (27917)
Utah (117)
Virginia (172)
Washington D.C. (37)
Washington State (693)
West Virginia (1)
Wisconsin (57)
287,807 Results for "wren therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Wren Laboratories Unveils Dynamic Executive Leadership Team and 2024 Commercial Strategy Overhaul
Wren Laboratories, a leader in novel in-vitro diagnostic technologies, announced significant enhancements to its executive leadership team.
June 17, 2024
·
5 min read
Genetown
Wren Therapeutics Renamed WaveBreak, Signifying Focus on Stopping the Wave of Neurodegeneration in Parkinson’s Disease, Alzheimer’s Disease, and ALS at its Source
Wren Therapeutics announced today that the company has changed its name to WaveBreak.
April 25, 2023
·
2 min read
Genetown
Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases
Wren Therapeutics announced a number of new members to its Scientific Advisory Board.
January 4, 2023
·
3 min read
Business
Wren Appoints Bart Henderson as Chief Executive Officer
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, announced the appointment of Bart Henderson as Chief Executive Officer.
March 4, 2022
·
2 min read
Business
Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
Wren Therapeutics announced today a number of senior leadership appointments as the company advances its first investigational therapies toward the clinic, based on the company’s breakthrough approach to discovering small molecules that precisely target and shut down the sources of oligomer and aggregate generation in neurodegenerative diseases.
December 8, 2022
·
5 min read
Wren Laboratories Dr. Mark Kidd to speak at 2024 Precision Medicine World Conference
The presentation will focus on the use of mRNA in Liquid Biopsies as a platform for precision diagnostics
January 19, 2024
·
1 min read
Genetown
Wren Presents Preclinical Data at AD/PD 2023 Demonstrating Potential of its First-in-Class, Small-Molecule Inhibitors of α-Synuclein Toxic Oligomers for the Treatment of Parkinson’s Disease
Wren announced today the presentation of preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating potent inhibition of both oligomer production and aggregate formation in cell and mouse models used for studying Parkinson’s disease progression.
March 29, 2023
·
6 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Press Releases
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
April 27, 2026
·
6 min read
Deals
Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)
Wren Therapeutics Ltd., a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, announced the closing of a £12.4 million financing.
January 25, 2021
·
5 min read
1 of 28,781
Next
